# Eli Lilly will acquire Boston-based cancer biotech Kelonia Therapeutics for $7 billion.

*business · news · 2026-04-20 · Boston.com*

## Key points

- Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront.
- Kelonia is developing an in vivo cell therapy platform for blood cancers, including multiple myeloma.
- Kelonia's platform could enable off-the-shelf gene therapies, mitigating manufacturing and access barriers.
- Eli Lilly has recently acquired Centessa Pharmaceuticals and Orna Therapeutics, expanding its Boston footprint.

**Companies:** Eli Lilly, Kelonia Therapeutics
**Countries:** United States

[Read the full story on Boston.com](https://www.boston.com/news/business/2026/04/20/eli-lilly-to-acquire-boston-biotech-kelonia-therapy-in-7-billion-deal/)

---

Canonical: https://newsio.io/n/89ff2d28-84c1-42f6-9c2b-a8651764dcc7/eli-lilly-will-acquire-boston-based-cancer-biotech-kelonia-therapeutics-for-7-bi
Summarized by Newsio from Boston.com. https://newsio.io/how-it-works